PeptideCompareVesugen — EU research guide.
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator series with proposed vasoprotective and geroprotective properties. Endothelial and vascular effects remain hypotheses based on group reviews rather than vascular studies. It is studied alongside Cardiogen as part of a broader cardiovascular bioregulator research cluster.
What is Vesugen?
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator series with proposed vasoprotective and geroprotective properties. Endothelial and vascular effects remain hypotheses based on group reviews rather than vascular studies. It is studied alongside Cardiogen as part of a broader cardiovascular bioregulator research cluster.
What does the research show?
Available research is limited to cell-culture, insect and animal-model work, group reviews and one review-level statement on memory and attention in elderly people; no human endothelial or vascular study was found. No independently replicated controlled human trial data is publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory use only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and declines as potency is lost. Above the dotted 80% line the material is considered reliable — hover the chart for exact values.
⚠ Estimates modelled per component from molecular properties (chain length, cyclisation, oxidation- and deamidation-sensitive residues, light sensitivity). Indicative only — not lab-measured per batch.
Vesugen is not yet in our price comparison
We expand EU supplier coverage every month.
References
- Cell-culture and honey-bee study of KED. It shows biological activity in vitro and in an insect, not an effect in a living mammal or in people. Chalisova NI, Lopatina NG, Kamishev NG, Linkova NS, Koncevaya EA, Dudkov AV, Kozina LS, Khavinson VKh, Titkov YuS. Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. Bull Exp Biol Med. 2012;153(4):569-572. DOI
- Narrative review by the Khavinson group on KED, gene expression and Alzheimer's disease. It is the source of the statement on oral KED and memory in elderly people, but the abstract gives no trial details. Khavinson VKh, Lin'kova NS, Umnov RS. Peptide KED: molecular-genetic aspects of neurogenesis regulation in Alzheimer's disease. Bull Exp Biol Med. 2021;171(2):190-193. DOI
- Review of ultrashort peptides in Alzheimer's disease. It describes KED effects on dendritic spines in a 5xFAD mouse model and on stem-cell differentiation in vitro, and it mentions no human trial of KED alone. Ilina A, Khavinson V, Linkova N, Petukhov M. Neuroepigenetic mechanisms of action of ultrashort peptides in Alzheimer's disease. Int J Mol Sci. 2022;23(8):4259. DOI
- Narrative review on senescence-associated secretory phenotype in cardiovascular cells. KED is named as a candidate regulator, but this is a review by the same group, not a vascular trial. Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K. Senescence-associated secretory phenotype of cardiovascular system cells and inflammaging: perspectives of peptide regulation. Cells. 2023;12(1):106. DOI
- Docking-model paper that lists Vesugen as the tripeptide Lys-Glu-Asp and predicts weak DNA binding. It is computational only and mainly confirms which sequence the name refers to. Khavinson VKh, Lin'kova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. DOI